Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,970 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Daily Radiation Therapy Clear all
Terminated Phase 1 Interventional Results available

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

NCT06056310
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 13, 2026, 5:48 PM EDT
Not listed Phase 1 Interventional

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

NCT00768911
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CT-322, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

NCT02314364
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1)
Interventions
SBRT with protons or photons
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00828009
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, Tecemotide, carboplatin, cyclophosphamide, paclitaxel, radiotherapy
Biological · Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
88
States / cities
Palo Alto, California • Stanford, California • Macon, Georgia + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 13, 2026, 5:48 PM EDT
Recruiting Phase 1 Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVax, Balstilimab, Zalifrelimab
Biological · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

NCT02474368
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
Interventions
Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT)
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

NCT06236516
View directory record Official record
Conditions
Lung Cancer, Oligometastatic Lung Tumor
Interventions
One fraction stereotactic body radiotherapy, HyperSight, Ethos
Radiation · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

NCT06065449
View directory record Official record
Conditions
Bone Metastases
Interventions
Radiation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

NCT04959474
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions
Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection
Other · Radiation · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Using a Head and Neck Maskless Immobilization Device For Patients With Intracranial Tumors

NCT03076255
View directory record Official record
Conditions
Brain and Nervous System, Intracranial Neoplasm, Head and Neck Cancer
Interventions
Computed Tomography, Medical Device, Cone-Beam Computed Tomography
Procedure · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 13, 2026, 5:48 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT03952585
View directory record Official record
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

NCT00813943
View directory record Official record
Conditions
Glioblastoma
Interventions
Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 13, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

NCT02678143
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil, Sirolimus, Fludarabine, Total body irradiation, Hematopoietic stem cell transplant
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

NCT00860574
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
treosulfan, fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, methotrexate
Drug · Radiation · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Early Phase 1 Interventional

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

NCT03158883
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
Avelumab, Stereotactic ablative radiotherapy (SAR)
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 13, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

Allo HSCT Using RIC and PTCy for Hematological Diseases

NCT05805605
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
Interventions
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

NCT01200602
View directory record Official record
Conditions
Anorexia, Weight Changes
Interventions
megestrol acetate, clinical observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Early Phase 1 Interventional Results available

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

NCT00140556
View directory record Official record
Conditions
Head and Neck Cancer, Pharynx Cancer
Interventions
Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib
Radiation · Drug
Lead sponsor
David M. Brizel, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 13, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional Results available

Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients

NCT04445337
View directory record Official record
Conditions
COVID 19, ARDS
Interventions
Stellate Ganglion Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 13, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

NCT00401401
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
zalutumumab, cisplatin, Radiotherapy
Drug · Procedure
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 22, 2011 · Synced Sep 13, 2026, 5:48 PM EDT
Terminated Early Phase 1 Interventional Results available

Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers

NCT03515941
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin, Capecitabine, Leucovorin, 5-fluorouracil, radiation
Drug · Radiation
Lead sponsor
Tannaz Armaghany
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 13, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

NCT06171269
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, MRI, Androgen Deprivation Therapy
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Project Persist: mHealth for Cancer Survivorship

NCT04126642
View directory record Official record
Conditions
Symptom Management, Reduce Treatment Non-adherence
Interventions
Assessment only group, Intervention group
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

NCT00033657
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
23
States / cities
Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 13, 2026, 5:48 PM EDT